160 results about "Kinin" patented technology

The invention belongs to the technical field of daily chemistry, and provides a triple compound acid composition with skin brightening and acne removing effects, a product and application of the triple compound acid composition and the product, the triple compound acid composition comprises mandelic acid, salicylic acid and succinic acid, and the mass ratio of the mandelic acid to the salicylic acid to the succinic acid is (3-6): (1-2): (1-2). The invention further provides a product containing the composition and application of the product. The composition provided by the invention is synergistically used, has a synergistic effect in the aspect of exfoliating, especially in the aspect of improving the activity of kallikrein 5 (KLK5), not only has the effects of biological skin glowing and exfoliating, but also can efficiently down-regulate the expression of I-type 5alpha-reductase genes, so that the synthesis of sebum is inhibited, and an oil control effect is achieved; in addition, the composition provided by the invention has the effects of brightening, inhibiting bacteria and resisting inflammation, has low sensitization, can be used for removing acnes, takes effect quickly and does not relapse.

The invention discloses an anti-human tissue kallikrein 1 monoclonal antibody and an application thereof. The anti-human tissue kallikrein 1 monoclonal antibody comprises any one of a monoclonal antibody CELL-2, a monoclonal antibody CELL-5 or a monoclonal antibody CELL-6 or a combination of at least two of the monoclonal antibody CELL-2, the monoclonal antibody CELL-5 and the monoclonal antibody CELL-6. The anti-human tissue kallikrein 1 monoclonal antibody provided by the invention is produced by immunizing natural tissue kallikrein, and can effectively recognize tissue kallikrein in human serum / urine.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

Disclosed herein include methods, compositions, and kits suitable for use in preventing or relieving side effects associated with the administration of a weight loss medication. The method can comprise administering to a subject under a weight loss treatment a composition comprising a neurokinin 1 receptor (NK1R) antagonist (e.g., aprepitant).

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS; diagnosing that the subject in undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject; and administering a therapeutically effective amount of treatment for RRMS to the subject.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The invention discloses a polypeptide composition for promoting skin desquamation and a preparation method and application thereof, the polypeptide composition comprises polypeptides and a polyol preservative, the polypeptides comprise a first polypeptide, a second polypeptide and a third polypeptide, and the first polypeptide is acetyl tetrapeptide-2; the second polypeptide comprises one or more of hyaluronic acid polypeptide, red scorpion toxin and palmitoyl tripeptide-5; and the third polypeptide is prepared from one or more of acetyl octapeptide-3, palmitoyl dipeptide-7, acetyl tetrapeptide-9 and acetyl tetrapeptide-11. The polypeptide composition can significantly up-regulate the gene expression of kallikrein through a synergistic effect and promote old cutin exfoliation; meanwhile, gene expression of metalloproteinase is inhibited, and light aging is delayed. The polypeptide composition disclosed by the invention can be prepared into various cosmetics and has multiple effects of promoting skin desquamation, resisting wrinkles and repairing barriers.

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Provided are methods and compositions for using tissue kallikrein-1 (KLK1) to treat or prevent pregnancy disorders such as fetal growth restriction (FGR) and preeclampsia.

Provided herein are methods of treating and preventing hereditary angioedema attack in pediatric subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 150 mg every two weeks or at about 150 mg every four weeks.

To provide a plasma kallikrein inhibitor and its use.SOLUTION: The present invention provides a compound and a composition thereof, which are useful as a plasma kallikrein inhibitor and exhibit desirable properties as the inhibitor.SELECTED DRAWING: None

The present invention provides compounds and compositions thereof that are useful as inhibitors of plasma kallikrein and that exhibit desirable properties toward said plasma kallikrein.

The invention provides a KIF18 inhibitor and a synthesis method thereof, and particularly provides a compound shown as a formula (I), and the compound can regulate KIF18A protein, so that the cell cycle and the cell proliferation process are influenced to treat cancers and cancer-related diseases. Also provided are pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more compounds of Formula I compounds, and methods for using the compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

The invention relates to a KIF18 inhibitor with a structure as shown in a formula (I) and a synthesis method thereof, and the compound can regulate KIF18A protein so as to influence a cell cycle and a cell proliferation process to treat cancers and cancer-related diseases. And pharmaceutical compositions comprising the compounds, methods for treating conditions associated with KIF18A activity.

Methods and compositions for controlling, treating, preventing, or ameliorating arthropod infection are provided. Compositions can comprise one or more active agents of small molecules antagonists of arthropod kinin receptor. Methods of preventing disease development and infestation by arthropods are disclosed as well as methods of making, using, and producing such compositions.

The present invention provides compounds of Formula (I):or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and / or inflammatory disorders using the same.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The present invention relates to human tissue kallikrein 7 (KLK7) selective inhibitor compounds, combinations including these compounds, process to obtain the referred compounds, and methods of using the same. The present invention belongs to the field of chemistry, pharmacology and medicine.

The application belongs to the technical field of cosmetics and skin external preparation, and discloses a retinoid, a preparation method and application thereof. The compound is formed by covalently coupling a Schiff base or a kinin releasing enzyme cleavable peptide bond (L) and a free L-amino acid, a di- to hexapeptide or a C6-C22 fatty acid ester (P) of the retinol parent (R), and the structural general formula is R-L-P. The compound has a 12-week stability rate of ≥80% in a 25℃ aqueous preparation, is recognized by a keratin layer carboxylic acid esterase and a kinin releasing enzyme KLK-5 / KLK-7 after being applied to the skin, is subjected to enzymatic cutting in a skin acidic cuticle (pH 4.5-5.5) microenvironment, and releases free retinol at a fixed point. Compared with retinol palmitate, the in-situ release efficiency of the compound of the application is increased by 2.5-4.5 times, while the risk of systemic absorption is significantly reduced, and the incidence of sensitive skin irritation is ≤6.7%.

The present invention describes the combination of a 5HT3-antagonist and / or NK1-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole for treating anhedonia.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.